Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients.
Toubai T, Tanaka J, Ota S, Fukuhara T, Hashino S, Kondo T, Kasai M, Kakinoki Y, Masauzi N, Morioka M, Kawamura T, Iwasaki H, Asaka M, Imamura M. Toubai T, et al. Among authors: kakinoki y. Am J Hematol. 2005 Nov;80(3):181-7. doi: 10.1002/ajh.20461. Am J Hematol. 2005. PMID: 16247752 Free article.
Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia.
Kikuchi M, Tanaka J, Kondo T, Hashino S, Kasai M, Kurosawa M, Iwasaki H, Morioka M, Kawamura T, Masauzi N, Fukuhara T, Kakinoki Y, Kobayashi H, Noto S, Asaka M, Imamura M. Kikuchi M, et al. Among authors: kakinoki y. Int J Hematol. 2010 Oct;92(3):481-9. doi: 10.1007/s12185-010-0670-1. Epub 2010 Sep 10. Int J Hematol. 2010. PMID: 20830615 Free article.
[Current status of treatment for patients with idiopathic thrombocytopenic purpura in the Hokkaido area (evaluation of Helicobacter pylori eradication)].
Hashino S, Ota S, Kobayashi S, Tanaka J, Musashi M, Fukuhara T, Miyake T, Kurosawa M, Iwasaki H, Shiroshita N, Hirano T, Irie T, Morioka M, Noto S, Kobayashi H, Suzuki S, Kawamura T, Yamamoto Y, Kakinoki Y, Kobayashi N, Kasai M, Oya T, Hirano M, Tanaka M, Fujimoto N, Imamura M; Clinical Hematology Forum. Hashino S, et al. Among authors: kakinoki y. Rinsho Ketsueki. 2004 Jul;45(7):539-45. Rinsho Ketsueki. 2004. PMID: 15359913 Japanese.
Effect of granulocyte colony-stimulating factor on IL-12 p40 production during chemotherapy for B-cell lineage non-Hodgkin's lymphoma patients.
Toubai T, Tanaka J, Ota S, Fukuhara T, Hashino S, Kondo T, Shono Y, Morioka M, Kawamura T, Masauzi N, Kakinoki Y, Kobayashi H, Kunieda Y, Kasai M, Kurosawa M, Asaka M, Imamura M. Toubai T, et al. Among authors: kakinoki y. Eur J Haematol. 2006 Nov;77(5):403-9. doi: 10.1111/j.1600-0609.2006.00746.x. Epub 2006 Aug 23. Eur J Haematol. 2006. PMID: 16930137 Free article. Clinical Trial.
Clinical efficacy and safety of first-line nilotinib therapy and evaluation of the clinical utility of the FRET-based drug sensitivity test.
Kondo T, Fujioka M, Fujisawa S, Sato K, Tsuda M, Miyagishima T, Mori A, Iwasaki H, Kakinoki Y, Yamamoto S, Haseyama Y, Ando S, Shindo M, Ota S, Kurosawa M, Ohba Y, Teshima T; North Japan Hematology Study Group (NJHSG). Kondo T, et al. Among authors: kakinoki y. Int J Hematol. 2019 Oct;110(4):482-489. doi: 10.1007/s12185-019-02696-w. Epub 2019 Jun 25. Int J Hematol. 2019. PMID: 31240558 Clinical Trial.
Non-age-related neoplastic loss of sex chromosome correlated with prolonged survival in real-world CBF-AML patients.
Mori A, Onozawa M, Hidaka D, Yokoyama S, Miyajima T, Yokoyama E, Ogasawara R, Izumiyama K, Saito M, Fujisawa S, Ota S, Kakinoki Y, Tsutsumi Y, Yamamoto S, Miyagishima T, Nagashima T, Iwasaki H, Kobayashi H, Haseyama Y, Kurosawa M, Morioka M, Teshima T, Kondo T. Mori A, et al. Among authors: kakinoki y. Int J Hematol. 2022 Feb;115(2):188-197. doi: 10.1007/s12185-021-03238-z. Epub 2021 Nov 5. Int J Hematol. 2022. PMID: 34739701
Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma.
Hashino S, Morioka M, Irie T, Shiroshita N, Kawamura T, Suzuki S, Iwasaki H, Umehara S, Kakinoki Y, Kurosawa M, Kahata K, Izumiyama K, Kobayashi H, Onozawa M, Takahata M, Fujisawa F, Kondo T, Asaka M. Hashino S, et al. Among authors: kakinoki y. Int J Lab Hematol. 2008 Aug;30(4):292-9. doi: 10.1111/j.1751-553X.2007.00955.x. Int J Lab Hematol. 2008. PMID: 18665826 Clinical Trial.
Ultra-high level of serum soluble interleukin-2 receptor at diagnosis predicts poor outcome for angioimmunoblastic T-cell lymphoma.
Shiratori S, Kosugi-Kanaya M, Shigematsu A, Kobayashi H, Yamamoto S, Kobayashi N, Iwasaki H, Mori A, Kunieda Y, Yutaka T, Kurosawa M, Kakinoki Y, Endo T, Kondo T, Hashino S, Teshima T; North Japan Hematology Study Group (NJHSG). Shiratori S, et al. Among authors: kakinoki y. Leuk Lymphoma. 2015;56(9):2592-7. doi: 10.3109/10428194.2014.1001985. Epub 2015 Feb 24. Leuk Lymphoma. 2015. PMID: 25563559
A Multicenter Retrospective Study of Mogamulizumab Efficacy in Adult T-Cell Leukemia/Lymphoma.
Iyama S, Sato T, Ohnishi H, Kanisawa Y, Ohta S, Kondo T, Mori A, Tsutsumi Y, Kuroda H, Kakinoki Y, Yamamoto S, Takahashi T, Shindo M, Torimoto Y, Sato K, Iwasaki H, Haseyama Y, Kohda K, Nagamachi Y, Hirayama Y, Sakai H, Hirata Y, Fukuhara T, Ikeda H, Kobune M, Kato J, Kurosawa M. Iyama S, et al. Among authors: kakinoki y. Clin Lymphoma Myeloma Leuk. 2017 Jan;17(1):23-30.e2. doi: 10.1016/j.clml.2016.09.009. Epub 2016 Sep 17. Clin Lymphoma Myeloma Leuk. 2017. PMID: 27727135
140 results